{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:32:00Z","timestamp":1795059120881,"version":"4.10.2"},"reference-count":56,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["MRSG-14-019-01-CDD"],"award-info":[{"award-number":["MRSG-14-019-01-CDD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["134170-MBG-19-174-01-MBG"],"award-info":[{"award-number":["134170-MBG-19-174-01-MBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","award":["G-22-1100"],"award-info":[{"award-number":["G-22-1100"]}],"id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","award":["NCI R37CA227865-01A1"],"award-info":[{"award-number":["NCI R37CA227865-01A1"]}],"id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","award":["NCI R01 CA281219"],"award-info":[{"award-number":["NCI R01 CA281219"]}],"id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA227865-01A1"],"award-info":[{"award-number":["R37CA227865-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA281219"],"award-info":[{"award-number":["R01CA281219"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006668","name":"Oregon Health and Science University","doi-asserted-by":"publisher","award":["P30 CA069533"],"award-info":[{"award-number":["P30 CA069533"]}],"id":[{"id":"10.13039\/100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008533","name":"Case Comprehensive Cancer Center, Case Western Reserve University","doi-asserted-by":"publisher","award":["P30 CA043703"],"award-info":[{"award-number":["P30 CA043703"]}],"id":[{"id":"10.13039\/100008533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008533","name":"Case Comprehensive Cancer Center, Case Western Reserve University","doi-asserted-by":"publisher","award":["GI SPORE 5P50CA150964-08"],"award-info":[{"award-number":["GI SPORE 5P50CA150964-08"]}],"id":[{"id":"10.13039\/100008533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment (TME) that limits the efficacy of immunotherapies. Many tumor-suppressive immune cells, including inflammatory macrophage subsets, rely on glycolysis to sustain effector function; however, the pancreatic TME is relatively glucose-limited. In this study, we investigated whether increasing glucose availability in the periphery, which in turn translates to increased intratumoral glucose, could enhance immune-based therapies in PDAC. In vitro, glucose restriction induced metabolic reprogramming of inflammatory (M1-like) macrophages toward an oxidative, M2-like state with reduced inflammatory effector markers. In immunocompetent mice, administration of 30% dextrose drinking water increased both peripheral and intratumoral glucose levels and modestly shifted tumor transcriptional profiles toward a more inflammatory state without altering overall immune cell abundance. When macrophage-targeting immunotherapies (colony stimulating factor 1 receptor inhibition with PLX3397 or C\u2013C chemokine receptor type 2 inhibition with PF-4136309) were combined with systemic hyperglycemia, tumors exhibited a pronounced increase in iNOS+ M1-like macrophages, a reduction in arginase+ M2-like macrophages, enhanced CD8+ T-cell infiltration, and decreased abundance of tumor-associated fibroblasts. These immunotherapies improved overall survival in immunocompetent mice bearing orthotopic pancreatic tumors only when combined with hyperglycemia. Analyses of patient samples confirmed the presence of a favorable antitumor immune infiltrate with elevated glucose levels. Together, these findings identify glucose availability as a key regulator of macrophage polarization and immunotherapy efficacy in PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>PDAC is largely resistant to immunotherapies. Our findings identify glucose availability in the TME as a modifiable determinant of macrophage polarization and immunotherapy response. In preclinical models, transient hyperglycemia was associated with enhanced efficacy of macrophage-targeting immunotherapies and promoted a more inflammatory TME.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0338","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:17:43Z","timestamp":1779369463000},"page":"1470-1485","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1608-8874","authenticated-orcid":false,"given":"Jonathan J.","family":"Hue","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01gc0wp38","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospitals Cleveland Medical Center 1 Division of Surgical Oncology, Department of Surgery, , Cleveland, Ohio."},{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 2 Department of Surgical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0127-1489","authenticated-orcid":false,"given":"Mehrdad","family":"Zarei","sequence":"additional","affiliation":[{"name":"3Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8066-9327","authenticated-orcid":false,"given":"Priyashree","family":"Sunita","sequence":"additional","affiliation":[{"name":"3Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9075-9496","authenticated-orcid":false,"given":"Sami O.","family":"Abul-Khoudoud","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01gc0wp38","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospitals Cleveland Medical Center 1 Division of Surgical Oncology, Department of Surgery, , Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8210-3219","authenticated-orcid":false,"given":"Goutam","family":"Dey","sequence":"additional","affiliation":[{"name":"3Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4370-8688","authenticated-orcid":false,"given":"Hallie J.","family":"Graor","sequence":"additional","affiliation":[{"name":"3Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-9455","authenticated-orcid":false,"given":"Katie E.","family":"Blise","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 4 Brenden-Colson Center for Pancreatic Care, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6104-3264","authenticated-orcid":false,"given":"Dove","family":"Keith","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 4 Brenden-Colson Center for Pancreatic Care, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5966-1522","authenticated-orcid":false,"given":"Shamilene","family":"Sivagnanam","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 5 Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Brenden Colson Center for Pancreatic Care, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1629-2648","authenticated-orcid":false,"given":"Shakti P.","family":"Pattanayak","sequence":"additional","affiliation":[{"name":"6Department of Biochemistry, School of Medicine, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2206-8124","authenticated-orcid":false,"given":"Erryk S.","family":"Katayama","sequence":"additional","affiliation":[{"name":"7Case Western Reserve University, Cleveland, Ohio."},{"name":"8The Ohio State University College of Medicine, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-5318","authenticated-orcid":false,"given":"Omid","family":"Hajihassani","sequence":"additional","affiliation":[{"name":"3Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-4932","authenticated-orcid":false,"given":"Charles D.","family":"Lopez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 4 Brenden-Colson Center for Pancreatic Care, , Portland, Oregon."},{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 9 Knight Cancer Institute, , Portland, Oregon."},{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 10 Department of Cell, Development and Cancer Biology, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1558-2413","authenticated-orcid":false,"given":"Rosalie C.","family":"Sears","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 4 Brenden-Colson Center for Pancreatic Care, , Portland, Oregon."},{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 9 Knight Cancer Institute, , Portland, Oregon."},{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 11 Department of Molecular and Medical Genetics, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-9327","authenticated-orcid":false,"given":"Robert","family":"Eil","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 12 Division of Surgical Oncology, Department of Surgery, Knight Cancer Institute, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2389-1865","authenticated-orcid":false,"given":"Lisa M.","family":"Coussens","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 5 Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute, Brenden Colson Center for Pancreatic Care, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3680-3270","authenticated-orcid":false,"given":"Jonathan R.","family":"Brody","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 4 Brenden-Colson Center for Pancreatic Care, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-8691","authenticated-orcid":false,"given":"Ali","family":"Vaziri-Gohar","sequence":"additional","affiliation":[{"name":"3Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio."},{"id":[{"id":"https:\/\/ror.org\/04b6x2g63","id-type":"ROR","asserted-by":"publisher"}],"name":"Loyola University Chicago 13 Department of Cancer Biology, Stritch School of Medicine, , Maywood, Illinois."},{"id":[{"id":"https:\/\/ror.org\/04b6x2g63","id-type":"ROR","asserted-by":"publisher"}],"name":"Loyola University Chicago 14 Department of Surgery, Stritch School of Medicine, , Maywood, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5200-6557","authenticated-orcid":false,"given":"Jordan M.","family":"Winter","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01gc0wp38","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospitals Cleveland Medical Center 1 Division of Surgical Oncology, Department of Surgery, , Cleveland, Ohio."},{"name":"3Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"2026062305415045000_bib1","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"2026062305415045000_bib2","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"2026062305415045000_bib3","volume-title":"NCCN Clinical Practice Guidelines in Oncology: pancreatic adenocarcinoma [Internet]","author":"National Comprehensive Cancer Network","year":"2025"},{"key":"2026062305415045000_bib4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.18632\/oncotarget.28739","article-title":"Exceptional responders to immunotherapy in pancreatic cancer: a multi-institutional case series of a rare occurrence","volume":"16","author":"Sugumar","year":"2025","journal-title":"Oncotarget"},{"key":"2026062305415045000_bib5","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.18632\/oncotarget.27727","article-title":"A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?","volume":"11","author":"Katayama","year":"2020","journal-title":"Oncotarget"},{"key":"2026062305415045000_bib6","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1038\/s41467-023-38921-8","article-title":"Increased glucose availability sensitizes pancreatic cancer to chemotherapy","volume":"14","author":"Vaziri-Gohar","year":"2023","journal-title":"Nat Commun"},{"key":"2026062305415045000_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41416-019-0479-5","article-title":"Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features","volume":"121","author":"Karamitopoulou","year":"2019","journal-title":"Br J Cancer"},{"key":"2026062305415045000_bib8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fimmu.2017.00289","article-title":"Macrophage metabolism as therapeutic target for cancer, atherosclerosis, and obesity","volume":"8","author":"Geeraerts","year":"2017","journal-title":"Front Immunol"},{"key":"2026062305415045000_bib9","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.2147\/CMAR.S196951","article-title":"Prognostic value of tumor-associated macrophages in pancreatic cancer: a meta-analysis","volume":"11","author":"Yu","year":"2019","journal-title":"Cancer Manag Res"},{"key":"2026062305415045000_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-019-0966-6","article-title":"TAMing pancreatic cancer: combat with a double edged sword","volume":"18","author":"Lankadasari","year":"2019","journal-title":"Mol Cancer"},{"key":"2026062305415045000_bib11","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.celrep.2018.03.131","article-title":"CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype","volume":"23","author":"Candido","year":"2018","journal-title":"Cell Rep"},{"key":"2026062305415045000_bib12","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-17-0162","article-title":"Stratification of pancreatic ductal adenocarcinoma: combinatorial genetic, stromal, and immunologic markers","volume":"23","author":"Knudsen","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026062305415045000_bib13","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/gutjnl-2017-313738","article-title":"Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma","volume":"67","author":"Nywening","year":"2018","journal-title":"Gut"},{"key":"2026062305415045000_bib14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026062305415045000_bib15","doi-asserted-by":"crossref","first-page":"1758835919854238","DOI":"10.1177\/1758835919854238","article-title":"Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors","volume":"11","author":"Wesolowski","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"2026062305415045000_bib16","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"key":"2026062305415045000_bib17","first-page":"e50966","article-title":"Bone marrow-derived macrophage production","volume":"18","author":"Trouplin","year":"2013","journal-title":"J Vis Exp"},{"key":"2026062305415045000_bib18","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s43018-022-00393-y","article-title":"Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors","volume":"3","author":"Vaziri-Gohar","year":"2022","journal-title":"Nat Cancer"},{"key":"2026062305415045000_bib19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/nprot.2012.024","article-title":"A positive\/negative ion\u2013switching, targeted mass spectrometry\u2013based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue","volume":"7","author":"Yuan","year":"2012","journal-title":"Nat Protoc"},{"key":"2026062305415045000_bib20","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.4161\/rna.25274","article-title":"HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer","volume":"10","author":"Burkhart","year":"2013","journal-title":"RNA Biol"},{"key":"2026062305415045000_bib21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41586-019-1004-y","article-title":"Hepatocytes direct the formation of a pro-metastatic niche in the liver","volume":"567","author":"Lee","year":"2019","journal-title":"Nature"},{"key":"2026062305415045000_bib22","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-16-0866","article-title":"Colony-stimulating factor 1 receptor blockade inhibits tumor growth by altering the polarization of tumor-associated macrophages in hepatocellular carcinoma","volume":"16","author":"Ao","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2026062305415045000_bib23","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1021\/ml200199c","article-title":"Discovery of INCB8761\/PF-4136309, a potent, selective, and orally bioavailable CCR2 antagonist","volume":"2","author":"Xue","year":"2011","journal-title":"ACS Med Chem Lett"},{"key":"2026062305415045000_bib24","first-page":"1","article-title":"High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers","volume":"635","author":"Banik","year":"2020","journal-title":"Methods Enzymol"},{"key":"2026062305415045000_bib25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.celrep.2017.03.037","article-title":"Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis","volume":"19","author":"Tsujikawa","year":"2017","journal-title":"Cell Rep"},{"key":"2026062305415045000_bib26","article-title":"Multiplex IHC image processing V0.2 v2 [Internet]","author":"Sivagnanam","year":"2023"},{"key":"2026062305415045000_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1109\/ISBIC56247.2022.9854534","article-title":"Nuclei instance segmentation and classification in histopathology images with Stardist","volume-title":"2022 IEEE International Symposium on Biomedical Imaging Challenges (ISBIC)","author":"Weigert","year":"2022"},{"key":"2026062305415045000_bib28","doi-asserted-by":"crossref","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","article-title":"CellProfiler: image analysis software for identifying and quantifying cell phenotypes","volume":"7","author":"Carpenter","year":"2006","journal-title":"Genome Biol"},{"key":"2026062305415045000_bib29","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1158\/2326-6066.CIR-23-0873","article-title":"Machine learning links T-cell function and spatial localization to neoadjuvant immunotherapy and clinical outcome in pancreatic cancer","volume":"12","author":"Blise","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"2026062305415045000_bib30","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3389\/fonc.2020.01696","article-title":"Humanized rodent models for cancer research","volume":"10","author":"Tian","year":"2020","journal-title":"Front Oncol"},{"key":"2026062305415045000_bib31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","article-title":"Targeting macrophages in cancer immunotherapy","volume":"6","author":"Duan","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026062305415045000_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2026062305415045000_bib33","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"key":"2026062305415045000_bib34","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1021\/acs.molpharmaceut.8b00237","article-title":"Modulating macrophage polarization through CCR2 inhibition and multivalent engagement","volume":"15","author":"Deci","year":"2018","journal-title":"Mol Pharm"},{"key":"2026062305415045000_bib35","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026062305415045000_bib36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"2026062305415045000_bib37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/jclinpath-2021-207781","article-title":"Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature","volume":"76","author":"Allen","year":"2023","journal-title":"J Clin Pathol"},{"key":"2026062305415045000_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1158\/1541-7786.MCR-22-0626","article-title":"BRAF-driven pancreatic cancer: prevalence, molecular features, and therapeutic opportunities","volume":"21","author":"Ciner","year":"2023","journal-title":"Mol Cancer Res"},{"key":"2026062305415045000_bib39","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026062305415045000_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C\u2013mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl J Med"},{"key":"2026062305415045000_bib41","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026062305415045000_bib42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s13402-021-00587-z","article-title":"Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel","volume":"44","author":"Brouwer","year":"2021","journal-title":"Cell Oncol"},{"key":"2026062305415045000_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00535-023-02058-8","article-title":"Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database","volume":"59","author":"Sakakida","year":"2024","journal-title":"J Gastroenterol"},{"key":"2026062305415045000_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026062305415045000_bib45","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair\u2013deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"2026062305415045000_bib46","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026062305415045000_bib47","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","article-title":"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study","volume":"25","author":"Van Laethem","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026062305415045000_bib48","doi-asserted-by":"crossref","first-page":"e2100437","DOI":"10.1200\/PO.21.00437","article-title":"Exceptional response to olaparib and pembrolizumab for pancreatic adenocarcinoma with germline BRCA1 mutation and high tumor mutation burden: case report and literature review","volume":"6","author":"Lundy","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026062305415045000_bib49","doi-asserted-by":"crossref","first-page":"e923803","DOI":"10.12659\/AJCR.923803","article-title":"Exceptional response to a single cycle of immunotherapy in a Lynch syndrome patient with metastatic pancreatic adenocarcinoma","volume":"21","author":"Patil","year":"2020","journal-title":"Am J Case Rep"},{"key":"2026062305415045000_bib50","doi-asserted-by":"crossref","first-page":"785400","DOI":"10.3389\/fimmu.2021.785400","article-title":"Successful immunotherapy for pancreatic cancer in a patient with TSC2 and SMAD4 mutations: a case report","volume":"12","author":"Ye","year":"2021","journal-title":"Front Immunol"},{"key":"2026062305415045000_bib51","doi-asserted-by":"crossref","first-page":"113220","DOI":"10.1016\/j.celrep.2023.113220","article-title":"Supplementation with a high-glucose drink stimulates anti-tumor immune responses to glioblastoma via gut microbiota modulation","volume":"42","author":"Kim","year":"2023","journal-title":"Cell Rep"},{"key":"2026062305415045000_bib52","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.imlet.2016.06.001","article-title":"Human monocytes and macrophages undergo M1-type inflammatory polarization in response to high levels of glucose","volume":"176","author":"Torres-Castro","year":"2016","journal-title":"Immunol Lett"},{"key":"2026062305415045000_bib53","doi-asserted-by":"crossref","first-page":"e41613","DOI":"10.1097\/MD.0000000000041613","article-title":"Unraveling the role of macrophages in diabetes: impaired phagocytic function and therapeutic prospects","volume":"104","author":"Rong","year":"2025","journal-title":"Medicine"},{"key":"2026062305415045000_bib54","volume-title":"Cabiralizumab misses primary end point in phase II trial of advanced pancreatic cancer [Internet]","author":"Ternyila","year":"2020"},{"key":"2026062305415045000_bib55","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.33312","article-title":"Long-term outcomes of pexidartinib in tenosynovial giant cell tumors","volume":"127","author":"Gelderblom","year":"2021","journal-title":"Cancer"},{"key":"2026062305415045000_bib56","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1038\/s41598-022-08163-7","article-title":"Preferential stimulation of melanocytes by M2 macrophages to produce melanin through vascular endothelial growth factor","volume":"12","author":"Han","year":"2022","journal-title":"Sci Rep"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0338\/3796536\/crc-25-0338.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/6\/1470\/3805431\/crc-25-0338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/6\/1470\/3805431\/crc-25-0338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:42:09Z","timestamp":1782207729000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/6\/1470\/786091\/Increased-Glucose-Availability-Sensitizes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0338","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32769850","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769820","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769841","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769826","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769814","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769847","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769817","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769805","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769838","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769799","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769811","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769844","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769832","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769802","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769835","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769823","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769808","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32769829","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8553229","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}